Allergan (NYSE:AGN) is one of the many biotech stocks that has been beaten down in the last one and a half year. In this article I will indicate 4 reasons why I think the company and the stock can perform well in the future.
Reason #1: Diversified sources of revenue and rich pipeline
One of the characteristics that I like in Allergan is its rich portfolio of drugs. As we can see....More>>>
bluebird bio, (NASDAQ:BLUE) is one of the oncology immunotherapy stocks I mentioned recently as worth a good look, (article titled ‘Immunotherapy Over Reaction’, a basic primer to the immunotherapy subsector and its ETF). BLUE is also a recent Cramer pick. Immunotherapy stocks have been hit hard over the summer but BLUE is a relatively highly valued genetic specialist, with some interesting....More>>>
Puma Biotechnology (NASDAQ:PBYI) ended the day down 13.8% after Roche (NASDAQOTH:RHHBY) reported that its rival breast cancer drug, Perjeta, had passed its phase 3 trial, dubbed “Aphinity.”
Image source: Getty Images.
In Roche’s trial, patients either took Perjeta and Herceptin with chemotherapy or just Herceptin with chemotherapy,....More>>>
One of the smaller details of Trumpcare, the redacted version of Obamacare, is the elimination of a tax imposed on manufacturers of medical devices. While the fate of pre-existing conditions has been hogging the spotlight in recent days, this particular tax and its future could have an impact on companies like Ventripoint Diagnostics (OTCMKTS: VPTDF TSE:VPT), and other small cap biotech....More>>>
Starting with a simple tweet on September 21st, 2015, Hillary Clinton has been pummeling Biotech stocks since her Presidential Campaign first began. In fact, Clinton has caused dramatic drops in the iShares Nasdaq Biotechnology ETF (IBB) at least three times in the past 14 months. The thought of Clinton winning the presidency, and the corresponding assault on the Biotech sector,....More>>>
Its been said of biotech that its the wild west of the investment world. There may be gold in the hills but you better have a good map and a keen eye to find it. One such company that is shimmering of late is Ventripoint Diagnostics (OTC: VPTDF), the Toronto, Ontario based developer of medical devices. With its new cardiac imaging device, the VMS Plus , Ventripoint is changing the way....More>>>
Apple (NASDAQ:AAPL) Pay Cash Card could increase Apple’s take-rate by 9 times, thereby accelerating the future growth of Apple’s Services revenue segment. With Apple Pay growing at 500% y/y, in a few years, Apple Pay Cash could add an incremental $1 billion to revenue. And given the infrastructure and cost per transaction not likely changing, we believe that most of this $1 billion will....More>>>
Like most of you, I don’t like to lose money. So you might be wondering why I was so quick to scoop up more shares of Gilead Sciences (NASDAQ:GILD) stock after its latest earnings report. After all, management shared a forecast for 2017 hepatitis C antiviral sales 39% lower than 2016 figures, and that’s at the high end of the provided range.
Before you assume I’ve completely....More>>>
Last year, Gilead Sciences (NASDAQ:GILD) managed a feat that very few of its peers ever have (or probably ever will): It shed a staggering $40 billion in value without a single top-selling drug going off patent.
GILD Market Cap data by YCharts.
In fact, the biotech actually launched multiple new products last year, such as the HIV medsOdefsey and Descovy, along with the latest addition....More>>>
William Patalon III
In a Private Briefing report in late July, we told you that tiny biotech Inovio Pharmaceuticals Inc. (Nasdaq: INO) had dosed its first patient in a Phase I clinical study to evaluate its synthetic vaccine for the Zika virus.
The announcement caught my eye for several reasons…
This is premium content for Private Briefing subscribers only.